AGP Executive Report
Last update: 4 hours agoAlzheimer’s Access: Canada’s Drug Agency gave a final positive recommendation for public reimbursement of LEQEMBI® (lecanemab) for early Alzheimer’s, moving eligible patients closer to coverage. Taiwan Health Policy: Taiwan’s MOHW rolled out expanded NHI coverage and higher IVF subsidies, plus broader eligibility for children’s dental fluoride treatment starting today. Rare Blood Cancer Update: The U.S. FDA approved PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia, the first new ET option in decades. Hospital Workflow Tech: Taipei Medical University Hospital deployed a smart specimen tube preparation system to cut nurses’ labeling and prep time and reduce sample errors. Food Safety Alert: Hong Kong’s food safety authority flagged a Taiwan-region pre-packed rice noodle product containing formaldehyde; consumers were urged to stop eating the affected batch. Industry Investment: Taiwan’s investment review approved major cases including Lam Research’s NT$9.835 billion Taiwan expansion for advanced semiconductor equipment R&D. Geopolitics & Health Diplomacy: Taiwan’s foreign minister showcased “Made in Taiwan” e-buses and energy cooperation in Palau alongside Pacific forum events.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
